Cancer-related microagiopathic hemolytic anemia in a patient with breast cancer – diagnostic difficulties | OncoReview

PDF

Published: Dec 31, 2020

DOI: https://doi.org/10.24292/01.OR.420231220

Keywords:

cancer-related microangiopathic hemolytic anemia, CR-MAHA, breast cancer, thrombotic microangiopathy, thrombocytopenia

Kamila Skwierawska

Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw

Krzysztof Woźniak

Department of Oncology, Medical University of Warsaw

Anna Waszczuk-Gajda

1. Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw. 2. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw

Joanna Drozd-Sokołowska

1. Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw. 2. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw

Piotr Kacprzyk

Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw

Marita Rachid Chehab

Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw

Piotr Boguradzki

1. Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw. 2. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw

Wiesław Wiktor Jędrzejczak

1. Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw. 2. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw

Grzegorz Władysław Basak

1. Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw. 2. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw

Abstract

Cancer-related microangiopathic hemolytic anemia is rarely recognized as a paraneoplastic syndrome with a very poor prognosis in cancer patients. The treatment and prognosis are significantly different from that in other thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. The case of described patient demonstrates the diagnostic difficulties in diagnosing the causes of hemolytic anemia in patient with breast cancer and appropriate treatment.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

How to Cite

1.

Skwierawska K, Woźniak K, Waszczuk-Gajda A, Drozd-Sokołowska J, Kacprzyk P, Chehab MR, Boguradzki P, Jędrzejczak WW, Basak GW. Cancer-related microagiopathic hemolytic anemia in a patient with breast cancer – diagnostic difficulties. OncoReview [Internet]. 2020Dec.31 [cited 2024Nov.22];10(4(40):134-8. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1143

Issue

Vol 10 No 4(40) (2020)

Section

HEMATO-ONCOLOGY

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012; 91(4): 195-205.
2. Takabatake D, Oishi K. Microangiopathic hemolytic anemia associated with metastatic breast cancer: case report and literature review. Springerplus. 2016; 5(1): 684. http://doi.org/10.1186/s40064-016-2312-4.
3. Regierer AC, Kuehnhardt D, Schulz C et al. Breast Cancer-Associated Thrombotic Microangiopathy. Breast Care. 2011; 6: 441-5.
4. Hausberg M, Felten H, Pfeffer S. Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer. Case Rep Oncol. 2019; 12: 1-6.
5. Lee EH, Otoukesh S, Abdi A et al. Hemolytic Anemia of Malignancy: A Case Study Involving Signet Ring Cell Metastatic Breast Cancer with Severe Microangiopathic Hemolytic Anemia. Case Rep Oncol. 2019; 12: 104-8.
6. Lara K, Bae E, Park H et al. A rare case of concurrent signet-ring carcinoma of breast and microangiopathic hemolytic anemia. J Surg Case Rep. 2016; (9): rjw132.
7. Morton JM, George JN. Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. J Oncol Pract. 2016; 12(6): 523-30.
8. Babu KG, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016; 10: 649.
9. Chalasani P, Segar JM, Marron M et al: Pathophysiology of tumour-induced microangiopathic haemolytic anaemia. BMJ Case Rep. 2016; 2016.
10. Werner TL, Agarwal N, Carney HM et al. Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol. 2007; 82(4): 295-8.
11. Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012; 30: 2601-8.
12. Meng X, Song S, Jiang ZF et al. Receptor conversion in metastatic breast cancer: a prognosticator of survival. Oncotarget. 2016; 7(44): 71887-903.